{
  "id": "5e30e80bfbd6abf43b00003b",
  "type": "factoid",
  "question": "Which molecule is targeted by Asciminib?",
  "ideal_answer": "Asciminib is an orally administered allosteric inhibitor of the BCR-ABL tyrosine kinase.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31006307",
    "http://www.ncbi.nlm.nih.gov/pubmed/28329763",
    "http://www.ncbi.nlm.nih.gov/pubmed/29568367",
    "http://www.ncbi.nlm.nih.gov/pubmed/31826340",
    "http://www.ncbi.nlm.nih.gov/pubmed/30927708",
    "http://www.ncbi.nlm.nih.gov/pubmed/29325229",
    "http://www.ncbi.nlm.nih.gov/pubmed/31543464",
    "http://www.ncbi.nlm.nih.gov/pubmed/30059193",
    "http://www.ncbi.nlm.nih.gov/pubmed/29522367",
    "http://www.ncbi.nlm.nih.gov/pubmed/30137981"
  ],
  "snippets": [
    {
      "text": "Asciminib, an allosteric ABL1 inhibitor, could demonstrate a higher capacity in overcoming common TKIs resistant mutations, including T315I, but clinical findings are needed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29522367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, allosteric targeting has been identified to consequentially inhibit Bcr-Abl activity, which led to the recent development of ABL-001 (asciminib) that selectively binds the myristoyl pocket.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29325229",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib (previously ABL001), which binds the myristate-binding pocket of the Bcr-Abl kinase domain, is in phase I clinical trials as monotherapy and in combination with imatinib, nilotinib and dasatinib for the treatment of patients with refractory CML or Ph+ ALL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29568367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib (ABL001) is an orally administered allosteric inhibitor of the BCR-ABL tyrosine kinase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30059193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137981",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We describe the discovery of asciminib (ABL001), the first allosteric BCR-ABL1 inhibitor to reach the clinic. Asciminib binds to the myristate pocket of BCR-ABL1 and maintains activity against TKI-resistant ATP-site mutations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we characterize ABL001 (asciminib), a potent and selective allosteric ABL1 inhibitor that is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28329763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We describe the discovery of asciminib (ABL001), the first allosteric BCR-ABL1 inhibitor to reach the clinic.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib binds to the myristate pocket of BCR-ABL1 and maintains activity against TKI-resistant ATP-site mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31006307",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Asciminib ( previously ABL001) , which binds the myristate-binding pocket of the Bcr-Abl kinase domain , is in phase I clinical trials as monotherapy and in combination with imatinib , nilotinib and dasatinib for the treatment of patients with refractory CML or Ph+ ALL . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29568367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein , locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31826340",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of Asciminib ( ABL001) , an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137981",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Asciminib binds to the myristate pocket of BCR-ABL1 and maintains activity against TKI-resistant ATP-site mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We describe the discovery of asciminib (ABL001), the first allosteric BCR-ABL1 inhibitor to reach the clinic.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib (previously ABL001), which binds the myristate-binding pocket of the Bcr-Abl kinase domain, is in phase I clinical trials as monotherapy and in combination with imatinib, nilotinib and dasatinib for the treatment of patients with refractory CML or Ph+ ALL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29568367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib, a highly selective non-ATP competitive inhibitor of BCR-ABL, has demonstrated to be a promising drug for patients with chronic myeloid leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30927708",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The obtained results indicate that the mutations have adversely influence on the binding of Asciminib to BCR-ABL, as the nonpolar contributions decline in the two mutants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30927708",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib is a potent, specific BCR-ABL1 inhibitor being developed for the treatment of patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31006307",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib, an allosteric inhibitor targeting the myristoyl-binding pocket of BCR-ABL1, is active against most single mutants but ineffective against all tested compound mutants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31543464",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we characterize ABL001 (asciminib), a potent and selective allosteric ABL1 inhibitor that is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive (Ph",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28329763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib, an allosteric ABL1 inhibitor, could demonstrate a higher capacity in overcoming common TKIs resistant mutations, including T315I, but clinical findings are needed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29522367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asciminib, an allosteric inhibitor targeting the myristoyl-binding pocket of BCR-ABL1, is active against most single mutants but ineffective against all tested compound mutants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31543464",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "BCR-ABL tyrosine kinase"
}